News & events

Webinar being held today “Evolving strategic context for phages, Introducing new opportunities” to present PHAXIAM Therapeutics strategy

organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scale

Cash and cash equivalents of €5.7 million as of September 30, 2024

PHAXIAM has received Investigational New Drug approval (IND) for its Phase II study, GLORIA, in Prosthetic Joint Infections (PJI) caused by Staphylococcus aureus (S. aureus). 

Sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)

Webinar (in French) today, September 25, 2024 at 6:00 pm CEST Click here to attend

The shareholders approved all the resolutions on which the Board of Directors recommended a favorable vote

Following the subscription period, which closed on June 25, 2024, total demand amounted to approximately 3.9 million shares, representing approximately €7.8 million, i.e. a subscription rate of around 77.1%:

Webinar (in French) on June 18, 2024, at 6:00 pm : Register here

Shareholders of PHAXIAM are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company’s registered office at 60 avenue Rockefeller – 69008 Lyon (France).